John L. Marquardt

John L. Marquardt, Jr., PhD

Counsel | Pharmaceutical
617.646.8189 I 301.213.7828 LinkedIn Profile


  • BS, Physics, Massachusetts Institute of Technology
  • PhD, Biochemistry and Molecular Pharmacology, Harvard University
  • MBA & JD, Georgetown University Law Center

Key Technologies

  • Small Molecule Pharmaceuticals
  • Biotherapeutics
  • Antibody Biotherapeutics
  • Antibody-drug Conjugates
  • RNA, DNA, Protein-based Biotherapeutics
  • CRISPR/Cas9/Gene Editing
  • Enzymes – Therapeutic & Commercial
  • Structural Biology Methods & Devices
  • Lipid Nanoparticle Delivery Systems
  • Viral Vector Delivery Technologies
  • Diagnostic Technologies

Practice Groups

Admitted to Practice

  • US Patent and Trademark Office
  • Virginia
  • District of Columbia
  • Massachusetts
  • United States District Court for the Eastern District of Virginia
  • United Stated District Court for the District of Columbia
  • United States Court of Appeals for Veterans Claims
  • United States Court of Appeals for the Federal Circuit


  • Washington, DC


John Marquardt focuses his practice on biotechnology and pharmaceutical patents. He has extensive experience in biochemistry and molecular pharmacology, and has applied his experience to aid in securing patent protection for multiple blockbuster drugs.

John draws on nearly 15 years of experience in scientific research at MIT, Harvard University, and the NIH. Known for his collaborative approach, John works closely with clients to achieve their goals through patent prosecution, counseling, and litigation. 

John’s laboratory experience includes work in genetic and protein engineering, macromolecular structure determination using nuclear magnetic resonance (NMR) spectroscopy and x-Ray crystallography, and modern drug-design.

John works on subject matter including traditional small-molecule drugs, gene therapies, protein therapeutics, monoclonal antibody therapies, diagnostic methods, and devices (electrochemiluminescent, fluorescent, radioactive, EPR, Raman active). His extensive experience in biochemistry and molecular pharmacology includes methods in molecular and cellular biology, immunology, microbiology, biochemistry, genomics, computational biology, small molecule pharmaceuticals, and biopharmaceuticals.

John is a frequent commentator, speaker, and author on patent law, specifically in the area of biosimilars. He has also lectured on strategic considerations under the Biologics Price Competition and Innovation Act (BPCIA).

While in law school, John served as an intern to the Honorable Randall R. Rader, in the US Court of Appeals for the Federal Circuit.


  • Monsanto v. Syngenta (D. Del.) - Defended against claims of infringement relating to two United States Patents involving technology for creation of herbicide resistant plants. Second chaired depositions of fact and expert witnesses relating to calculation of damages.
  • Telcordia v. Cisco, Lucent and Alcatel (D. Del.) - Asserted three patents relating to telecommunications protocols against defendants. Managed extensive offensive and defensive electronic discovery.
  • Wyeth Effexor XR® Litigations - Asserted three patents in ANDA litigations relating to Effexor XR® against 14 defendants. Supervised three junior attorneys and three consultants in extensive offensive and defensive electronic discovery in litigation asserting three patents against defendants. Second chaired depositions of expert witnesses.
  • Prosecuted patent applications relating to novel pharmaceutical compositions and formulations. The compositions included novel families of small molecule therapeutics; protein based therapeutics, including monoclonal and therapeutic antibodies; and nucleotide based therapeutics, including RNAi, microRNA, antisense and nucleotide analogues.
  • Prosecuted applications relating to electrochemiluminescent diagnostic devices and reagents. The electrochemiluminescent assays included enzyme linked immunoassays. Managed three junior attorneys over the course of four years in prosecution applications relating to diagnostic devices and reagents employing Raman spectroscopic detection. These included enzyme conjugated immunoassays and labeled antibody assays employing novel chemistry and methods for detection.
  • Participated in Examiner interviews with the USPTO. Prepared materials for reexamination and patent opposition proceedings. Obtained patent term extensions and supplementary protection certificates extending patent term.
  • Performed extensive pre-litigation review of English and Japanese language documents, totaling more than 500,000 pages, relating to a drug with sales in excess of $2 billion per year in preparation for ANDA challenge.


  • Biotechnology Committee and Chemical Practice Group, American Intellectual Property Law Association (AIPLA)
  • Editorial board of mAbs - an international, peer-reviewed journal


  • John L Marquardt, Stephen R Auten, “Strategic considerations under the Biologics Price Competition and Innovation Act.” Expert Opinion on Therapeutic Patents 23(8) (2013). DOI:10.1517/13543776.2013.813935


John enjoys sailing on the Chesapeake Bay with his wife and three children. He loves to run or walk with his wife and/or dog along the Potomac River.